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The Synthesis and Chemistry of Certain 
Anthelmintic Benzimidazoles 
LB. Townsend and D.S. Wise 
A basis for interest in the benzimidazole ring system as a nucleus 
from which to develop potential chemotherapeutic agents was 
established in the I95Os when it was found that 5,6-dimethyl- I - 
(a-D-ribofiranosyljbenzimidazole (I) was an integral part ofthe 
structure of vitamin 6,~ As a result of these interests and 
extensive studies, one health related arena that has benefited 
greatly has been the treatment ofparasitic diseases. The discovery 
of thiabendazole in I96 I further spurred chemists around the 
world to design and synthesize several thousand benzimidazoles 
for screening for anthelmirltic activity but less than twenty ofthem 
have reached commercial use. Much ofthis work has been done 
by pharmaceutical companies and is only reported in the patent 
literature. In this paper, Leroy Townsend and Dean Wise review 
the development ofsome cfthe synthetic methods that have been 
critical to the preparation of the benzimidazoles ofanthelmintic 
importance. On/y a few ,nolecules that demonstrate the pro- 
cesses are discussed here, but numerous reviews of the synthesis 
andchemistry ofother benzimidazoles are available’“. 
Box I. Tautomerism and isomerism 
The systematic numbering of the benzimidazole ring system is 
shown in structure 1. Although benzimidazole is depicted in I as 
pssessing the proton at N,, there actually exists a rapid 
Exchange between the -NlH- and =N- nitrogen atoms, and two 
tautomers, I and II, may be drawn for the benzimidazole mol- 





; I 9 
7 
I II 
ecule. Tautomerism occurs through either an intermolecular 
process involving two or more benzimidazole molecules or 
through interactions witlh a protic solvent such as water. It 
renders the 5- and 6- positions, and any group at that position in 
the ring system, chemically equivalent. In N-substituted benzimi- 
dazoles, tautomerism is no longer possible and two distinct 
non-equivalent molecules or isomers may be isolated and charac- 
terized. For example, the two dimethylated benzimidazoles 
shown are an isomeric pair of non-equivalent molecules, while 
the mono-methylated molecules are tautomers and equivalent. 
Benzimidazole, as the name implies, is a bicyclic ring system in 
which benzene has been fused to the 4- and 5-position of the 
heterocycle (imidazole; Box I). Benzimidazole compounds in 
general, and benzimidazole carbamates in particular, are crys- 
talline materials, with fairly high melting points and are relatively 
insoluble in water. Compounds that are unsubstituted on 
either of the imidazole nitrogen atoms possess both acidic and 
basic characteristics. 
Modifications of the benzimidazole ring system that have 
been made during the search for anthelmintic activity are 
summarized in Box 2. Combinations of the modifications at 
positions 2- and 5- of the molecule has provided the most 
active drugs. The synthetic pathways to the various benzimi- 
dazoles usually proceeds through two steps, first the construc- 
tion of a benzene ring containing the desired substituents and a 
I ,2-diamine grouping, followed by the ring closure of the 
I ,2-diaminobenzene (o-phenylenediamine) derivative to con- 
struct the imidazole ring. In many cases, this ring closure is the 





o - phenylenediamine 
R, R’ = ring substitution 
final step in the synthesis of the desired benzimidazole. How- 
ever, in other instances this ring closure is followed by exten- 
sive derivatization of the ring system or of the existing 
exocyclic substituents (Box 3). 
The discovery4 in I96 I that 2-(4’-thiazolyl)benzimidazole 
(thiabendazole) possessed a very potent broad spectrum of 
activity against gastrointestinal parasites was the breakthrough 
that opened up a new era in the treatment of parasitic diseases. 
In the initial studies, a group of researchers at Merck prepared 
thiabendazole by a condensation of o-phenylenediamine with 
thiazole-4-carboxamide in the presence of the dehydrating 




general in nature and several hundred derivatives, including the 
2-(2’-furyl)-,2-phenyl-,2-(2’-naphthyl)-, and 2-(S’-thiazoyl)- 
congeners, were also prepared to determine the best candi- 
date for commercial development. Both the 2-phenyl- deriva- 
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Box 2. Chemical Structures of Some Benzimidazole Anthelmintics 
Benzimidazoles Benzimidazole Carbamates 
NHCO&H, 
R = H Thiabendazole 
crystals, mp 304°C 
insoluble in water, slightly soluble in alcohol 
R = 1 \ i _ Mebendazole” 
o- 
crystals, acetic acid, mp 288°C 
insoluble in water - 
R = (CH,),CHOCONH- Cambendazole 
crystals, mp 238°C 
insoluble in water, soluble in alcohol 
i _ FIubendazole’” 
crystals, mp 280°C 




a , NHCO,Me 
crystals, mp 250°C 
’ 1 N=C<NHCWe e&$;lmp ,29”c 
R I CH3CHfiHaS- Albendazole” \ NHCOCH,OCH, crystals, mp 208°C 
R = CHsCH$H20 - ;;i$ia;;t;&C 
practically insoluble in water 
Netobimin 
crystals, water soluble 
; 
a ‘I NHC-NHCO,Me Thiophanate (methyl) \ NHCNHCO,Me crystals, soluble in alcohol 
k! 
R = CH,CH&H,CH,- 
Parbendazoleg crystals, 
mp 225°C. insoluble in water 
studied further. A new, efficient procedure for the conversion 
of N-arylamidines with hypochlorite and a base to form 
benzimidazoles was devised by the Merck group5, and this 
discovery made it economically practical to market the 
2-phenyl derivative and thiabendazole. In this procedure it is 
unnecessary to prepare the o-phenylenediamine compound 
because aniline is used as a starting material. Thus, to prepare 
thiabendazole (4) aniline is reacted with 4-cyanothiazole (2) in 
the presence of aluminium trichloride (a Lewis acid), to give the 
intermediate N-arylamidine hydrochloride (3). The critical 
oxidative cyclization to give (4) is then carried out by treating 
(3) with sodium hypochlorite in the presence of a base. The 
latter reaction has been accomplished commercially in one 
step, but it may also be performed stepwise through the 
intermediate (5). 
ltwas later found that both thiabendazoleand 2-phenylbenz 
imidazole suffer from an enzymatic hydroxylation at the 
S-position to give (a), which inactivates the drug and therefore 
Since hydroxylation was occurring at the 5-position, analogs 
of thiabendazole with different groups at this position were 
developed. As a potential candidate, 5-aminothiabendazole (9) 
was prepared by a condensation of 4-nitrophenylenediamine 
(7) with (2) to furnish 5-nitrothiabendazole (8). The nitro 
group of compound (8) was then reduced to furnish 5- 
aminothiabendazole (9). Compound (9) was nearly (80%) as 






enzymatic i!zzzFHOW;m 9 H ~~‘:‘, 
6 
limits its effectiveness. To overcome this problem, investi- 
gators began to prepare second generation benzimidazoles H 
with structural modifications that might prevent metabolic IO cambendazole 
inactivation. These studies led to an abundance of potential functional portion of (9) with isopropyl chloroformate pro- 
anthelmintic benzimidazoles, and many methods of prep- duced the 5-isoproxycarbonylamino derivative (I 0), which 
aration. was marketed under the name cambendazole’. Later, 
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thiabendazole 
IO II 
cambendazole was prepared directly from thiabendazole by 
an electrophilic substitution of a nitrene or nitrene-like 
intermediate derived from isopropyl azidoformate, initiated 
by heat or UV light7. Another unique synthesis of cambenda- 
zole involves a reduction of the 3-(4-thiazolyl)benzotriazine 
I -oxide ( I I)‘. 
Through a systematic study involving a modification of the 
thiazole ring at the 2-position of thiabendazole, workers at 
Smith Kline and French found that the thiocarbonate com- 
pound (I 2a) possessed anthelmintic activity’. This led to the 
preparation of 2-acylarninobenzimidazoles (I Zb), 2-benz- 
a = ’ ONpNH!,, .N 
H 




imidazolylcarbamates (I I!c) and 2-benzimidazolylureas (I 2d). 
All of these compounds ‘possessed anthelmintic activity, how- 
ever, the 2-methylcarbamate derivative stood out as the most 
effective. Several compounds were prepared that possessed 
thisgroupatthe2-position.Oneofthesecompounds,prepared 
by the reaction of 4-but+o-phenylenediamine (I 3) with car- 
bomethoxycyanamide (14) in boiling propanol, was methyl 
5-butyl-2-benzimidazolylcarbamate (I 5; parbendazole). 
Following the introduction of this compound, additional 
drugs were produced by several pharmaceutical companies. 
Janssen Pharmaceutics produced mebendazole, flubendazole, 
and ciclobendazole” among others; Smith Kline and French 
discovered al bendazole ’ ’ , oxibendazole ’ 2, and fenbenda- 
zole13; and Syntex developed oxfendazole’4. To prepare 
these benzimidazoles, several new ring closing reagents were 
H 
I3 I4 15 parbendazole 
employed or invented and these 2-methoxycarbamate 
synthons are shown in Table I. 
To prepare mebendazole, flubendazole, ciclobendazole, 
and a variety of benzimidazoles containing a group attached to 
the 5-position of the benzimidazole by a carbonyl (C=O) 
linkage, a general reaction scheme was developed by re- 
searchers at Janssen (see Box 3). In this synthetic sequence, the 
initial step is to append to ring A, the group which becomes the 
5-carbonyl linked substituent. This is accomplished using a 
Box 3. Examples of Benzimidazole Modifications Undertaken to Effect Anthelmintic Activity 
Carbon 5 and 6 - Modifications Heterocyclic Modifications Carbon I-Modification 
r-l 
R = aromatic, OR’, NHR’ 
R = alkyl, aromatic ring 
heterocyclic ring 
- $NHR 
\ YH O II s 
/ = CNHR’, COR’, -C-NW’ 
R = alkyl, aromatic ring 
R = alkyl, aromatic ring 
R = methly, ethyl, etc. 
Table I. Reagents used for the formation of methyl benzimidazole 
Structure 
CH,S, 




C = N-C02CH3 
H 




C = N-CO&H, 
NC - NH CO2CH3 
c’\ 
































I - SMe :: 
HN*C- NHCO,Me HN&.NH, + Cl-COCH, 
mebendazole 
flubendazole 
clclobendazole R = b 
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classical Friedel-Craft acylation with either an aromatic or 
aliphatic acid chloride and methoxy- or chlorobenzene to give 
(I 6). Compound (I 6) is then converted to (I 7) by nitration at 
the site adjacent to the methoxyl- or chloro- group. Alterna- 
tively, the 3-nitro-4-chloro derivative (I 7) could be made in 
one step by acylation of 3-nitro-4-chlorobenzoyl chloride. 
Owing to the electron donating effects of the adjacent nitro 
group, the 4-methoxy or chloro group is readily converted to 
the 3-nitro-4-aniline derivative (18). Reduction of the nitro 
group by a variety of methods gives (I 9) which is ring closed 
to the desired benzimidazole using methoxycarbonyl-S- 
methylisothiourea. 
To prepare oxfendazole I4 the necessary diamine (24) IS 
prepared by a series of reactions including a nucleophilic 
20 21 22 
23 24 
oxfendazole 
substrtution of the chloro moiety of 2-amino-4- 
chloronitrobenzene (20) with thiophenol(2 I) in the presence 
of potassium carbonate. This reaction affords 2-amino-4- 
phenylsulfurylnitrobenzene (22). Oxidation of (22) with one 
equivalent of peracetic acid gives the sulfoxide (23) which is 
selectively hydrogenated to give (24). Oxfendazole is obtained 
by an annulation of the diamine system of (24) with I ,3-bis- 
(methoxycarbonyl)-S-methylisothiourea. 
The synthetic steps required to prepare albendazole’ I fur- 
ther illustrate how the benzene ring may be modified before 
ring closure to the benzimidazole system. In this five step 
synthesis, 4-chloro-2-nitroaniline (25) is first acetylated 
with acetic anhydride to give I -acetamido-4-chloro-2-nitro- 
benzene (26). Treatment of (26) with potassium thiocyan- 
ate furnishes the key intermediate I -acetamido-2-nitro-4- 
thiocyanatobenzene (27). Conversion of the thiocyanato 
group of (27) into the required n-propylthio- analog, with a 
simultaneous conversion of the acetamido group to the free 
amine, is effected by treating(27) with I -bromopropane in the 
presence of a base. Reduction of the nitro group of (28) 
provides the diamine (29) which is subsequently ring closed to 
albendazole. 
In an alternative synthesis, mebendazole has also been 
reported” to be prepared in good yield from benzo-2, I ,4- 
thiadiazines. 2-Amino-4-benzoyl-nitrobenzene (30) was con- 














densed with methoxycarbonyl isothiocyanate to give an o-nitr- 
oarylthiocarbamoylcarbamate (3 I). Reduction with sodium 
dithionite gives the key intermediate benzo-2, I ,4-thiadiazine 





Both mebendazole and flubendazole have been prepared in 
an improved overall yield by a series of reactions shown 
below. In this synthesis**, the key step is a ring closure of the 
appropriate diamine with methoxycarbonyl isothiocyanate, in 
the presence of dicyclohexyl carbodiimide (DDC) in aceto- 
nitrile. The overall yields are 77% of mebendazole and 55% of 
flubendazole, respectively. 
Poor drug absorption and lack of water solubility are 
problems that limit the use of most benzimidazole carbamates 
against intestinal parasites. In addition, recently developed 
resistance to the curre,It commercially available drugs by 
certain parasites is also cf concern, and together these prob- 
lems have prompted the development of new benzimidazole 
carbamate types. Among these are heterocyclic isosteres, 
compounds which contain a heterocyclic core other than 
benzimidazole. Prodrugs are being developed that are appro- 
priately substituted benzene molecules that are enzymatically 
converted to an active benzimidazole carbamate after absorp- 
tion by the animal under treatment. 
A series of 6-substituted imidazo[ I ,2-olpyridine-2- 
carbamates have been prepared23, and one of these (40) has 
shown higher activity than any known benzimidazole against 
X = F,H 
certain parasites. To synthesize (40), the picoline (34) is pre- 
pared by the addition of chlorine to 5-ethynyl-2-methylpyrid- 
ine (33) and is subsequently dehydrohalogenated with a strong 
base to furnish the 5-trichloro substituted intermediate (35). 
Four more synthetic steps (35-39) are necessary in order to 
convert the 2-methyl group of (35) to the 2-amino derivative 
(39). Ring cyclization of (39) with methyl (chloroacetyl) carba- 
mate produced the target compound (40). This compound is 
still under investigation. 
33 34 35 
36 37 38 
Cl 
CI,C=l / n I ‘N NH, 
39 40 
Examples of prodrugs are thiofhanate (methyl) (41)24, 
febantel (42)25 and netobimin (43)* ; all of which are conver- 
ted to benzimidazole carbamates by the host. For example, 






netobimin (43) has been shown to undergo a reduction of the 
nitro group by microflora of the intestine”. The resulting ‘- 
ortho amino derivative cyclizes to methyl S-(propylthio)benz- 











accomplished by treatment of the 5-methylisothiourea deriva- 
tive (45) with taurine. It should be noted that netobimin as a salt 
is freely soluble in water and, as such, has major advantages 
over the benzimidazoles per se. This is an area of research that 
has great promise. 
We have attempted to show a few examples of benzimida- 
zole syntheses that have shown great value to humankind. 
Does the synthesis of new benzimidazoles still have merit, and 
is research in this area still going on? The answer is yes. 
Resistance to the now commercially available benzimidazoles 
has developed and poor oral absorption remain problems 
which have yet to be solved. 
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Mode of Action of Benzimidazoles 
E. Lacey 
Benzimidazoles represent the only class of 
truly broad-spectrum anthelmintics, how- 
ever, they also show activity against fungi 
and mammalian cells. This raises the ques- 
tion as to why benzimidazoles can selec- 
tively kill helminths and yet exhibit little or 
no mammalian toxicity. In this paper, 
Ernest Lacey examines this example of 
selectivity of drug action to the ubiquitous 
target of these drugs, the structural pro- 
tein, tubulin. 
With the discovery of thiabendazole in 
I96 I, the general pattern of benzimida- 
zoles (BZs) as a class of low-dose broad- 
spectrum anthelmintics with a high 
therapeutic index was established ’ The 
subsequent cascade of patents during 
the next 25 years led to the experimen- 
tal or commercial development of a fur- 
ther I5 BZs (see pp IO7- I I 2, this issue) 
and BZ prodrugs. Central to the success 
of BZs is their selective toxicity for hel- 
minths. Since the mid- 1960s the mode of 
action of BZs has been extensively inves- 
tigated and our understanding of how 
BZs act has undergone radical reappral- 
sa12d. In a recent review, Lacey4 con- 
eluded that despite the diverse effects of 
BZs at the biochemical and cellular levels, 
the primary mode of action of these 
drugs involves their interaction with the 
eukaryotic cytoskeletal protein, tubulin. 
This paper examines the paradox of the 
interaction of BZs with a ubiquitous pro- 
tein and the evidence for their selective 
toxicity for helminths. 
Tubulin and Microtubules 
The microtubule subunit, tubulin, is a 
dimeric protein comprised of c1- and 
P-subunits of approximately 50 kDa 
each5. Structurally, both a- and P-tubu- 
lins are heterogeneous proteins, prod- 
ucts of multi-gene families as well as 
post-translational modifications. The se- 
quences of tubulins from a wide diversity 
of species have been reported, and 
show a high degree of homology5. 
Microtubules exist in dynamic equilib- 
rium with tubulin, the ratio of dimeric 
tubulin to polymeric microtubules being 
controlled by a range of endogenous re- 
gulatory proteins and co-factors (Fig. I p. 
This equilibrium can be altered, both in 
vivo and in vitro, by exogenous sub- 
stances known as microtubule InhIbItor% 
Most, but not all, such inhibitors exert 
their action by binding to tubulin to pre- 
vent the self-association of subunits onto 
the growing microtubules. This results in 
a ‘capping’ of the microtubule at the 
associating end while the microtubule 
continues to dissociate from the oppos- 
ing end, with a net loss of microtubule 
length. One implication of this phenom- 
enon is that it is not necessary for inhibi- 
tors to bind all tubulin dimers to inhibit 
polymerization, it is sufficient for them 
simply to’cap’the microtubule. 
Microtubule inhibitors are a group of 
structurally diverse compounds pro- 
duced by fungi, plants, marine organisms, 
possibly higher eukatyotic animals and, 
more recently, synthetically. They show 
a wide spectrum of selective and non- 
selective toxicity against eukaryotic 
genera. Some of the well-characterized 
microtubule inhibitors, such as vinblas- 
tine and vincristine, have found a use in 
cancer chemotherapy, but most are too 
toxic for therapeutic use. 
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